DDInter1524 DDInter1676
A derivative of procaine with less CNS action.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Procainamide {u} (Compound) resembles {v} (Compound) Aminohippurate
Procainamide {u} (Compound) resembles {v} (Compound) Procaine
Procainamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metoclopramide
Procainamide {u} (Compound) binds {v} (Gene) SCN11A
Procainamide {u} (Compound) causes {v} (Side Effect) Vomiting
Procainamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Alosetron
Procainamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Infliximab
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Procainamide {u} may lead to a major life threatening interaction when taken with {v} Ivosidenib
Procainamide {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Procainamide (Compound) resembles Aminohippurate (Compound)
Procainamide (Compound) resembles Procaine (Compound)
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Procainamide (Compound) binds SCN11A (Gene)
Procainamide (Compound) causes Vomiting (Side Effect)
Procainamide may cause a minor interaction that can limit clinical effects when taken with Alosetron
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Infliximab
Procainamide may lead to a major life threatening interaction when taken with Cladribine
Procainamide may lead to a major life threatening interaction when taken with Ivosidenib
Procainamide (Compound) resembles Lidocaine (Compound) and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine